Stefan F Vermeulen
Biographic Data
| ID | 9700534 |
|---|---|
| NAME | Stefan F Vermeulen |
| GIVEN NAMES | Stefan F |
| FAMILY NAME | Vermeulen |
| SIGNATURE | VERMEULEN S F |
| AFFILIATIONS | Erasmus MC |
| ORCID | 0000-0002-8797-9172 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
The ‘false hope’ argument in discussions on expanded access to investigational drugs
When seriously ill patients reach the end of the standard treatment trajectory for their condition, they may qualify for the use of unapproved, investigational drugs regulated via expanded access programs. In medical-ethical discourse, it is often argued that expanded access to investigational drugs raises ‘false hope’ among patients and is therefore undesirable. We set out to investigate what is meant by the false hope argument in this discourse…
Factors of feasibility
Seriously ill patients who have exhausted all approved treatment regimens and who cannot be enrolled in clinical trials may resort to expanded access programmes in order to gain access to unapproved, investigational drugs. It seems that in some countries, expanded access to investigational drugs is offered in clinical practice on a more routine basis than in other countries. This study is the first to investigate the experiences of physicians wit…
No prominent works on this page.
Factors of feasibility
Seriously ill patients who have exhausted all approved treatment regimens and who cannot be enrolled in clinical trials may resort to expanded access programmes in order to gain access to unapproved, investigational drugs. It seems that in some countries, expanded access to investigational drugs is offered in clinical practice on a more routine basis than in other countries. This study is the first to investigate the experiences of physicians wit…
The ‘false hope’ argument in discussions on expanded access to investigational drugs
When seriously ill patients reach the end of the standard treatment trajectory for their condition, they may qualify for the use of unapproved, investigational drugs regulated via expanded access programs. In medical-ethical discourse, it is often argued that expanded access to investigational drugs raises ‘false hope’ among patients and is therefore undesirable. We set out to investigate what is meant by the false hope argument in this discourse…
Biomedical Ethics and Regulation (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Medicine (2 works) · Political science (2 works) · Access to medicines (1 work) · Alternative medicine (1 work) · Business (1 work) · Clinical trial (1 work) · Epistemology (1 work) · Expanded access (1 work)